| Literature DB >> 35056620 |
Petr Jaroš1, Maria Vrublevskaya2, Kristýna Lokočová2, Jana Michailidu2, Irena Kolouchová2, Kateřina Demnerová1.
Abstract
The use of antibiotics or antifungals to control infections caused by pathogenic microorganisms is currently insufficiently effective because of their emerging resistance. Thanks to the ability of microorganisms to form a biofilm and thus increase their resistance to administered drugs even more, modern medicine faces the task of finding novel substances to combat infections caused by them. In this regard, the effects of essential oils or plant extracts are often studied. Among the relatively neglected plants is Boswellia serrata, which has a high content of biologically active boswellic acids. In this study, we focused on one of the most common nosocomial infections, which are caused by Candida species. The most common representative is C. albicans, although the number of infections caused by non-albicans species has recently been increasing. We focused on the antifungal activity of Boswellia serrata extract Bioswellix against planktonic and adhering cells of Candida albicans, Candida parapsilosis and Candida krusei. The antifungal activity against adhering cells was further explored by determining the metabolic activity of cells (MTT) and determining the total amount of biofilm using crystal violet. Boswellic acid-containing plant extract was shown to suppress the growth of a suspension population of all tested Candida species. Boswellia serrata extract Bioswellix was most effective in inhibiting C. albicans biofilm formation.Entities:
Keywords: Candida albicans; Candida krusei; Candida parapsilosis; biofilm; boswellic acid; fluconazole
Year: 2022 PMID: 35056620 PMCID: PMC8778954 DOI: 10.3390/microorganisms10010171
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Minimum inhibitory concentrations (MIC50) of Bioswellix and fluconazole for C. albicans ATCC 2091, C. parapsilosis CCM 8260 and C. krusei CCM 8271.
| MIC50 (mg L−1) | Microorganism | ||
|---|---|---|---|
| Bioswellix (EtOH) | 200 | 280 | 250 |
| Bioswellix (DMSO) | 80 | 120 | 20 |
| Bioswellix (medium) | 500 † | 500 † | 500 † |
| Fluconazole | 20 | 35 | 50 |
† has not been determined up to the above concentration.
Minimum biofilm inhibitor concentrations (MBIC50) of Bioswellix and fluconazole for C. albicans ATCC 2091, C. parapsilosis CCM 8260 and C. krusei CCM 8271.
| MBIC50 (mg L−1) | Microorganism | ||
|---|---|---|---|
| Bioswellix (DMSO) | 500 † | 500 † | 100 |
| Fluconazole | 75 | 100 † | 100 † |
† has not been determined up to the above concentration.
Figure 1Effect of Boswellia serrata extract Bioswellix on C. albicans ATCC 2091, C. parapsilosis CCM 8260 and C. krusei CCM 8271. Biofilm metabolic activity (A); total biofilm biomass (B); control 100% (no agent). Error bars represent standard deviation.
Figure 2Effect of fluconazole on C. albicans ATCC 2091, C. parapsilosis CCM 8260 and C. krusei CCM 8271. Biofilm metabolic activity of (A); total biofilm biomass (B); control 100% (no agent). Error bars represent standard deviation.
Figure 3Effect of Bioswellix on C. albicans ATCC 2091 biofilm formation (visualized by a Cellavista device), scale bar 100 μm.
Figure 4Effect of fluconazole on C. albicans ATCC 2091 biofilm formation (visualized by a Cellavista device), scale bar 100 μm.